All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Celltrion secures Health Canada go-ahead for Eylea biosimilar

South Korean biopharma Celltrion has obtained regulatory approval for its Eylea (aflibercept) biosimilar, Eydenzelt, from Health Canada. The therapy will…
Over half of European HIV patients diagnosed late, ECDC report finds

A European 2025 HIV/AIDS surveillance report has revealed that countries within the continent are currently failing to test and treat…
SK bolsters oncology pipeline in radiopharmaceutical licensing deal

SK Biopharmaceuticals has in-licensed its second radiopharmaceutical – this time from a US-based academic organisation – in a bid to…
Novartis axes 550 jobs at Swiss manufacturing site

Novartis has announced plans to lay off 550 staff at its site in Stein, Switzerland, by the end of 2027.…
Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m

Gilead Sciences has secured the rights to Sprint Bioscience’s preclinical oncology programme for up to $400m, sending Sprint’s stock soaring…

Veeva Summit Europe: future-proofed AI set to bolster commercial pharma operations

At the 2025 Veeva Commercial Summit Europe, AI and its role in pharma and the wider life sciences industry was…
GLP-1RA Alzheimer’s hopes dashed after Novo Nordisk’s semaglutide miss

Novo Nordisk’s Rybelsus (oral semaglutide) has failed to demonstrate efficacy in a late-stage trial in Alzheimer’s disease, denting hopes of…
Early planning, outsourcing and digitalisation to break down CGT CMC barriers

Since their inception, cell and gene therapies (CGTs) have shown great promise in treating a plethora of challenging diseases. Despite…
Novartis taps North Carolina as new manufacturing hub location

Novartis has settled on North Carolina as the home for three of its newest manufacturing facilities, which will see the…
Alkermes prevails over Lundbeck in Avadel bidding war

Alkermes appears to have successfully hit back with a counteroffer to buy sleep disorder drugmaker Avadel, following Lundbeck’s last-minute bid…